Healthcare’s Once-in-a-Generation Disruption
The cost of healthcare in the United States continues to rise and the availability continues to decline. Healthcare spending accounts for 18% of U.S. GDP, and the costs in the U.S. are the highest in the world, increasing 130% in just the last decade. With this complexity comes an opportunity for entrepreneurs, innovators, and investors. iSelect is focused on finding technologies and innovations that reduce costs, increase accessibility, and improve quality of care.
iSelect Portfolio Companies
iSelect focuses on early-stage healthcare companies that are poised to help push the next healthcare revolution forward. We deliberately invest in companies that can make a positive impact on our society, as well as on the bottom line.
Neuros Medical, Inc.
Neuros Medical, a medical device company, develops an electrical nerve block to treat chronic pain for conditions including neuroma/residual limb pain and chronic post-surgical pain. Learn more… 
Cocoon Biotech, Inc.
Fibroin is an insoluble protein that is responsible for silk’s structure and tensile strength. Additional physical properties include tunable viscosity, anti-inflammatory, and wound healing attributes. Cocoon’s fibroin is expected to yield substantial improvements in use-cases such as bio-preservatives, drug or small/molecule delivery, natural lubricants, and hydrogels across numerous industries including human and animal health, agriculture, and consumer products. Learn more…
Nix, Inc.
Nix is developing a wearable, single-use patch that monitors hydration in real-time, without the need for a power-source or companion device/app. Learn more…
MOBILion Systems
MOBILion Systems Inc. has developed ion mobility technology that can separate and identify previously undetectable, clinically significant molecules within minutes, enabling far more accurate disease diagnosis, biomarker discovery, drug discovery, and clinical trial design among other potential applications. Learn more…
Shield Bio
Shield Bio is enabling 3rd generation sequencing to more rapidly and cost effectively diagnose and treat infectious disease while fighting antimicrobial resistance. Learn more…
Molecular Assemblies
Molecular Assemblies is developing an enzymatic DNA synthesis platform technology, enabling new products in industrial synthetic biology, personalized therapeutics, precision diagnostics, data storage, nanotechnology and more. Molecular Assemblies’ novel enzymatic DNA synthesis platform has the potential to fundamentally transform how we write genetic building blocks with applications across food, healthcare, energy, and beyond. Learn more…
Healionics, Inc.
Healionics, Inc. has developed a novel bio-material called STAR, that features strong anti-infective properties and significant reduction in the formation of scar tissue around implanted medical devices coated with the material. Learn more…
Holobiome, Inc.
Holobiome is developing a platform for microbiome-based therapeutics to treat diseases of the central and enteric nervous systems. Learn more…
SciBac, Inc.
SciBac is developing a platform technology called MERGE that enables the Company to efficiently combine desired traits of two microbes into one stable hybrid organism through lab-induced directed evolution. Learn more…
GeneMatters, LLC
GeneMatters is a digital health platform that provides scalable, on-demand genetic counseling to meet the rapidly growing demand for genetic services. Learn more…
Flywheel Exchange, LLC
Flywheel offers a SaaS platform that provides cloud-scale data management and computational analysis. Learn more…
Cofactor Genomics, Inc.
Cofactor Genomics uses proprietary RNA sequencing (“RNA-Seq”) technology and machine learning algorithms to diagnose disease. Learn more…
Entac Medical, Inc.
Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Previs Audio Spectral Analysis. Their first product is used to predict post operative ileus after GI surgeries. Learn more…
Indalo Therapeutics
Indalo Therapeutics is developing novel small-molecule therapeutics to differentially treat and prevent the rapidly growing class of fibrotic diseases affecting millions globally. Learn more…
CareSignal
Epharmix is a healthcare software company substantially reducing the cost of care for chronic diseases using text messaging. Learn more…
Gila Therapeutics, Inc.
Gila Therapeutics is developing a treatment for obesity using naturally occurring hormones known to induce satiety, leading to weight loss. Learn more…
Euclises Pharmaceuticals, Inc.
Euclises Pharmaceuticals is developing novel enzyme (COX-2) inhibitors designed to increase the effectiveness of chemotherapy safely Learn more…
Immunophotonics, Inc.
Immunophotonics has developed a minimally invasive therapeutic cancer vaccine for the treatment of metastatic solid tumors. Learn more…
Meet Our Selection Committee
Our Healthcare Selection Committee consists of industry and subject matter experts who help guide iSelect’s investment decisions. With firsthand experience and a true pulse on the industry, we consider these individuals key to our success in finding and investing in healthcare innovation.
Resources and News
Are We Really Ready for Genetic Testing?
There’s a lot we still don’t know about the power of genetic testing. For one thing, it’s becoming more powerful than ever expected. Already, patients can get gene-based information about their cancer risk, for instance, as well as details about genetic disorders that might impact their children, autism diagnoses, and more.
Enabling the Next Generation of Healthcare IT
It’s been a long time coming, but technology is finally transforming the healthcare industry, enabling functions and services that were all but unimaginable just a few years ago. Case in point: data.
Who Has Your DNA? Why Data Privacy Is the Next Battleground in Consumer Genetics
Genetics is changing the world as we know it, and not only in the realm of healthcare and medical science. Whether it’s 23andMe delivering specific details about our ancestry, genetic science being used to united people who have been switched at birth, or even DNA information being used to catch the Golden State Killer, there is much that genomics can now accomplish.
Humanity Is Dehydrated, and It Doesn’t Even Know It Yet
One thing is for sure: we’re not drinking enough water. None of us. And it’s damaging our health. That was the message of a recent article in The New York Times.
Dehydration Nation: Preventing One of the Most Common Health Risks in Real-Time
Up to three-fourths of Americans are chronically dehydrated, and the condition can be far more debilitating than it might seem. Mild dehydration — literally, not drinking enough water on a day-to-day basis — can impair cognitive performance by up to 20%, affecting reaction time, mental accuracy and memory. More severe cases, however, can result can result in seizures, brain damage, shock, and death.
RNA Is Becoming the New DNA, Opening New Doors in Medicine
If a person’s DNA is the roadmap of their lifetime health, their RNA is more of a real-time barometer, recording what happens in their body on a minute-by-minute basis. Our DNA stores and transfers genetic information, but remains little changed throughout our lives. At best, it can tell us about the probability we will someday develop various diseases — whether or not we will get cancer, for instance, or be susceptible to diabetes or heart disease — but it can’t tell us much about our current health.
Flywheel: Accelerating Discoveries By Creating an App Store for Science
Flywheel is building an archive of scientific developments, methods and tools so that future researchers will be able to build on those discoveries.
GeneMatters: How Genetic Testing Is Pushing Us Toward Medicine’s Next Frontier
Genetic testing has gone mainstream — consider examples like 23andMe and even Ancestry.com, which both offer genetic analysis by mail — and the market is on track to exceed $10 billion in the next several years.
What iSelect Is Looking For in the Companies It Invests In
So people ask me what the optimal, or perfect, iSelect investment opportunity looks like. And there's a scientific, or a finance type of answer that I can give you that we're looking for a company that has an opportunity to have a 10 times return to our investor, or...
![[PODCAST] Cofactor Genomics and the Future of Personalized Medicine](https://www.iselectfund.com/wp-content/uploads/2017/11/Cofactor_Genomics_Lobby-1080x675.jpg)
[PODCAST] Cofactor Genomics and the Future of Personalized Medicine
On today's podcast, Cofactor Genomics COO, Dr. David Messina discusses how his company is working to make personalized medicine a reality by focusing on the potential of RNA as a diagnostic tool. Unlike DNA, which is set in stone at birth, our RNA changes on a...
Gila Therapeutics Completes Phase I Clinical Trial
Obesity drug developer, Gila Therapeutics, recently took a big step toward FDA approval for its new weight control treatment, completing its Phase I clinical trial in August. Gila is developing a novel intra-oral delivery of PYY, a well-known satiety hormone, to help...
DNA, RNA and the Coming Reality of Personalized Medicine
Medicine has always been a science of averages. Most people in the population tend to suffer from most of the same diseases, and most of those diseases respond to most of the same treatments. If one therapy doesn’t work, doctors always have other drugs and other...
